Liminatus Pharma (LIMN) Financial Statements
Liminatus Pharma Financial Overview
Liminatus Pharma's market cap is currently $3.79M. The company's EPS TTM is $-23.70; its P/E ratio is -0.12; Liminatus Pharma is scheduled to report earnings on ―, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Gross Profit | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Operating Income | $ -2.97M | $ -2.91M | $ -2.59M | $ -2.71M | $ -2.53M |
| EBITDA | $ -9.99M | $ -2.75M | $ -1.09M | $ -2.71M | $ 4.37M |
| Net Income | $ -10.21M | $ -2.90M | $ -1.23M | $ -2.93M | $ 4.37M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 337.65K | $ 804.54K | $ 434.00K | $ 5.05M | $ 336.23K |
| Total Assets | $ 512.79K | $ 2.83M | $ 4.50M | $ 15.49M | $ 276.44M |
| Total Debt | $ 1.44M | $ 5.12M | $ 16.05M | $ 16.50M | $ 90.00K |
| Net Debt | $ 1.10M | $ 4.32M | $ 15.62M | $ 11.45M | $ -246.23K |
| Total Liabilities | $ 10.33M | $ 18.70M | $ 15.19M | $ 14.19M | $ 21.57M |
| Stockholders' Equity | $ -9.81M | $ -15.87M | $ -10.69M | $ 1.29M | $ 254.87M |
| Cash Flow | |||||
| Free Cash Flow | $ -9.98M | $ -3.11M | $ -3.35M | $ -869.00K | $ -1.22M |
| Operating Cash Flow | $ -9.96M | $ -3.11M | $ -3.35M | $ -869.00K | $ -1.22M |
| Investing Cash Flow | $ -788.11K | $ 1.97M | $ -819.00K | $ 0.00 | $ -276.00M |
| Financing Cash Flow | $ 11.03M | $ 1.05M | $ -450.00K | $ 5.92M | $ 277.55M |
Currency in USD